Religious leaders in South Africa have slammed Statements made by the United States of America about Afrikaners More than 300 Christian leaders signed a statement against the claims that white people ...

LONDON — An experimental weight loss drug from Novo Nordisk helped patients shed a substantial amount of weight in an early-stage trial, the company said Friday, providing a boost for Novo as ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% jump in the Danish drugmaker’s share price in premarket trading.

"Maybe this can help regain some faith in Novo's pipeline," he added. Earlier last year, a daily-pill version of Novo's amycretin was shown to lead to 13.1% weight loss after just 12 weeks ...

Novo Nordisk A/S rose the most since August 2023 after its experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

With a bit of maintenance, they'll age like your favorite leather jacket. At $300, the Jeremy Allen White specials aren’t cheap, exactly, but for shoes this handsome, they're an absolute steal.

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

Novo Nordisk is also developing amycretin as a once-daily pill, with trial results indicating a 13.1% weight reduction. However, this formulation was associated with numerous side effects.